Does Aldosterone Cause Hypertension by a Non-Renal Mechanism?
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00553722 |
Recruitment Status : Unknown
Verified October 2007 by Shaare Zedek Medical Center.
Recruitment status was: Not yet recruiting
First Posted : November 6, 2007
Last Update Posted : November 6, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypertension Dialysis Hyperaldosteronism | Drug: Eplerenone Drug: Placebo | Phase 4 |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 27 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Diagnostic |
Official Title: | Does Aldosterone Cause Hypertension by a Non-Renal Mechanism? |
Study Start Date : | November 2007 |
Estimated Study Completion Date : | November 2009 |

Arm | Intervention/treatment |
---|---|
Experimental: Eplerenone
Administer Eplerenone, 25 mg, orally twice daily for 4 weeks.
|
Drug: Eplerenone
Administer Eplerenone, 25 mg,orally twice daily for 4 weeks. |
Placebo Comparator: placebo
Administer a placebo tablet orally twice daily for 4 weeks
|
Drug: Placebo
Administer a placebo tablet orally twice daily for 4 weeks. |
- Significant drop in blood pressure with Eplerenone when compared to placebo. [ Time Frame: days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years to 80 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- We will select study participants from adult hemodialysis patients treated thrice weekly at Shaare Zedek Medical Center Dialysis Unit.
- Men and women will qualify for the study if they were on hemodialysis therapy for more than 3 months, have an average predialysis plasma potassium concentration less than 5.6 mEq/L at the time of enrollment and have nil or minimal urine output (<500 mL/24 h).
- All participating women of childbearing age will have a negative pregnancy test result before entering into the study.
Exclusion Criteria:
Exclusion criteria will include:
- A known allergy to Spironolactone or Eplerenone
- Any acute illness; hypotension, defined as a predialysis systolic blood pressure less than 100 mm Hg
- Severe hypertension (predialysis systolic blood pressure >180 mm Hg and/or diastolic blood pressure >100 mm Hg)
- Decompensated heart failure
- Inability to give informed consent; and
- Noncompliance.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00553722
Contact: Linda Shavit, MD | 02 6555086 | lshavit@szmc.org.il | |
Contact: Itzchak Slotki, MD | o2 6555085 | islotki@szmc.org.il |
Israel | |
Shaare Zedek Medical Center | |
Jerusalem, Israel, 91031 | |
Contact: Linda Shavit, MD 02 6555086 lshavit@szmc.org.il | |
Principal Investigator: Linda Shavit, MD |
Principal Investigator: | Linda Shavit, MD | Shaare Zedek Medical Center |
ClinicalTrials.gov Identifier: | NCT00553722 |
Other Study ID Numbers: |
1-Shavit |
First Posted: | November 6, 2007 Key Record Dates |
Last Update Posted: | November 6, 2007 |
Last Verified: | October 2007 |
hypertension dialysis hyperaldosteronism |
Hypertension Hyperaldosteronism Vascular Diseases Cardiovascular Diseases Adrenocortical Hyperfunction Adrenal Gland Diseases Endocrine System Diseases Eplerenone |
Mineralocorticoid Receptor Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Diuretics, Potassium Sparing Diuretics Natriuretic Agents Antihypertensive Agents |